BPH/LUTS and ED: common pharmacological pathways for a common treatment

Area of Science:

• Urology
• Pharmacology
• Men's Health

Background:

• Lower urinary tract symptoms (LUTS) and erectile dysfunction (ED) are common in aging men.
• These conditions often coexist and may share common pathophysiological mechanisms.
• Current treatments for LUTS include alpha-adrenergic blockers and 5-alpha-reductase inhibitors.

Purpose of the Study:

• To review the literature on shared physiopathogenetic factors of LUTS and ED.
• To explore the role of phosphodiesterase type 5 inhibitors (PDE5-Is) in managing LUTS and ED.
• To discuss implications for diagnosis and treatment strategies.

Main Methods:

• A comprehensive literature search was performed.
• Keywords included "lower urinary tract symptoms (LUTS)", "erectile dysfunction (ED)", and "phosphodiesterase type 5 inhibitors (PDE5-Is)".
• Original articles, reviews, editorials, and abstracts were identified.

Main Results:

• Manuscripts revealed common pathophysiological mechanisms linking LUTS and ED.
• PDE5-Is emerged as a potential alternative or adjunctive therapy for LUTS.
• Randomized controlled trials demonstrated that PDE5-Is improve both LUTS and ED concurrently.

Conclusions:

• Shared pathophysiological pathways between LUTS and ED are increasingly recognized.
• Further research is needed to fully elucidate these mechanisms.
• Comparative studies of different PDE5-Is are warranted to optimize treatment regimens and assess efficacy/safety profiles.